PT-141 in women: onset and side effects

Questions about how PT-141 (bremelanotide) works in women, how quickly it takes effect, and what side effects to expect come up constantly in community forums. The short answer is that bremelanotide is the only FDA-approved melanocortin receptor agonist for women, so the answer to those questions does not have to rest on anecdote. The RECONNECT Phase 3 programme enrolled 1,247 premenopausal women^[1] and the Vyleesi prescribing information documents the pharmacokinetic timeline and adverse-event rates directly^[2]. This article pulls the numbers that matter for women considering this drug.

Onset: how long before the effects arrive

The FDA-approved label specifies that Vyleesi should be administered at least 45 minutes before anticipated sexual activity^[2]. That 45-minute window reflects bremelanotide's pharmacokinetic profile: the drug reaches peak plasma concentration roughly 60 minutes after subcutaneous injection. The mechanism is central, not peripheral. Bremelanotide activates MC3R and MC4R melanocortin receptors in the hypothalamus, which are involved in sexual-desire circuitry, rather than acting on genital vasculature the way sildenafil does. That central route accounts for the longer lead time compared with on-demand erectile-dysfunction drugs.

Women in the RECONNECT trials self-administered the drug on an as-needed basis for 24 weeks. The design was explicit: dosing happened before anticipated activity, not on a fixed schedule. That fits with how most real-world users approach it, though the label sets the outer limit at one dose per 24-hour period and no more than eight doses per month.

Side effects in the trial population: the actual numbers

Three adverse events reached 10% or more in the bremelanotide group across both RECONNECT studies^[1]: nausea, flushing, and headache. The prescribing information gives specific rates from the controlled phase: nausea 40% (versus 1.3% on placebo), flushing 20.3%, injection-site reactions 13.2%, headache 11.3%, and vomiting 4.8%^[2]. Most were mild to moderate in intensity.

Nausea is the signal that shapes user experience most. The label reports that nausea typically began within one hour of dosing and lasted about two hours. Peak incidence occurred after the first dose (21% of participants) and fell to roughly 3% with subsequent doses^[2]. The 52-week open-label extension (Simon et al. 2019, n=684) found that the overall nausea rate did not meaningfully attenuate with continued on-demand use: 40.4% reported nausea across the extension period, and no new safety signals emerged^[3].

One practical note from the label: taking oral ondansetron 30 minutes before injection does not reduce nausea incidence and is not recommended by Cosette Pharmaceuticals^[2]. The standard antiemetic workaround used by some community members does not have label support.

Blood pressure and the cardiovascular picture

Every dose of bremelanotide produces a transient, predictable blood-pressure rise. The label reports maximum mean increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours post-dose and returning to baseline within 12 hours^[2]. Heart rate drops by up to 5 beats per minute on the same timeline.

For most healthy premenopausal women this transient shift is not clinically significant. The label lists uncontrolled hypertension and known cardiovascular disease as the only two formal contraindications. Anyone with either condition should not use this drug.

What the trial evidence shows about efficacy

The RECONNECT programme (studies BMT-301 and BMT-302, Kingsberg et al. 2019) used two co-primary endpoints: change in the FSFI desire-domain score and change in FSDS-DAO item 13 (a single-item sexual-distress measure). Across the integrated dataset, bremelanotide produced statistically significant improvements on both: desire-score increase of 0.35 and distress-score decrease of 0.33, both with p less than 0.001^[1]. Effect sizes were modest, and the authors described them accurately as such.

A 2022 subgroup analysis of the same RECONNECT data (Simon et al. 2022) found that the improvements held across age, BMI, and testosterone quartiles, and across both women using hormonal contraceptives and those who were not^[4]. A 2026 systematic review and meta-analysis by Toledo and colleagues, covering 36 studies of treatments for female sexual desire, arousal, and orgasmic dysfunction, found that bremelanotide improved total FSFI scores and the desire and arousal subscales specifically^[5].

What sits outside the evidence base

The entire Vyleesi dataset comes from premenopausal women with diagnosed HSDD. Postmenopausal women, men, and people using bremelanotide without an HSDD diagnosis fall outside the trial populations. There are no controlled AE rates for those groups. For the regulatory status of PT-141 in your country, see the PT-141 regulation pages.

Grey-market 'PT-141' research vials available from online vendors are not Vyleesi. Their purity and dose accuracy are unverified, and the trial data does not transfer to unlicensed products. The side-effect rates above apply to the FDA-regulated product administered at the approved dose.

Two gaps in the evidence are worth flagging. First, long-term hyperpigmentation: the label reports focal skin darkening in roughly 1% of patients at the approved on-demand schedule, with higher frequency in people with darker baseline skin tone, and states that resolution was not confirmed in all cases after stopping treatment. Second, the cardiovascular data covers the 45-minute pre-activity window and the 12-hour return to baseline, but longer-term cardiovascular outcomes were not a powered endpoint in any bremelanotide trial.